Somatic mutations in healthy tissues contribute to aging, neurodegeneration, and cancer initiation, yet remain largely uncharacterized. To gain a better understanding of their distribution and functional impacts, we leveraged the genomic information contained in the transcriptome to uniformly call somatic mutations from over 7,500 tissue samples, representing 36 distinct tissues. This catalog, containing over 280,000 mutations, revealed a wide diversity of tissuespecific mutation profiles associated with gene expression levels and chromatin states. We found pervasive negative selection acting on missense and nonsense mutations, except for mutations previously observed in cancer samples, which were under positive selection and were highly enriched in many healthy tissues. These findings reveal fundamental patterns of tissue-specific somatic evolution and shed light on aging and the earliest stages of tumorigenesis.
INTRODUCTION
In humans, somatic mutations play a key role in senescence and tumorigenesis 1 . Pioneering work on somatic evolution in cancer has led to the characterization of cancer driver genes 2 and mutation signatures 3 ; the interplay between chromatin, nuclear architecture, carcinogens and the mutational landscape [4] [5] [6] [7] ; the evolutionary forces acting on somatic mutations [8] [9] [10] [11] ; and clinical implications of somatic mutations 12 .
Compared to cancer research, the study of somatic mutations in healthy tissues is limited. Early studies focused on blood 13, 14 as it is readily accessible and because of the known effects of immune-driven somatic mutation. Recently, somatic mutations have been characterized in tissues like skin 15 , brain 16, 17 , esophagus 18, 19 and colon 20 . These studies confirmed that cells harboring certain mutations expand clonally, and the number of clonal populations-as well as the total number of somatic mutations-increases with age. Additionally, recurrent positivelyselected mutations in specific genes (e.g. NOTCH1) were observed. However, a more comprehensive understanding of somatic mutations across the human body has been limited by the small number of tissues studied to date.
Most studies on somatic evolution in healthy tissues have sequenced DNA from biopsies to high coverage. However, the transcriptome also carries all the genomic information of a cell's transcribed genome, in addition to RNA-specific mutations or edits. RNA-seq has been used to identify germline DNA variants 21 , and recently single-cell (sc) RNA-seq was used to call DNA somatic mutations in the pancreas of several people 22 .
To systematically identify somatic mutations in the human body and to investigate their distribution and functional impact, we developed a method that leverages the genomic information carried by RNA to identify DNA somatic mutations while avoiding most sources of false positives. We applied it to infer somatic mutations across 36 non-cancerous tissues, allowing us to explore the landscape of somatic mutations throughout the human body. Figure 1 . A method to iden�fy DNA soma�c muta�ons from RNA-seq. a, A general overview of the method. RNA-seq reads were downloaded from GTEx v7 (le�) and processed to iden�fy posi�ons with two different base calls at a high confidence. Then, sources of biological and technical ar�facts were removed (right, see Methods). b, Schema�c illustra�ng poten�al sources of sequence varia�on. c, Average percentage of variants detected in blood RNA-seq that are retained a�er each step of filtering (see Methods). d, Valida�on of the method. For 105 individuals we compared variant calls from exome DNA-seq data with those from RNA-seq of the same samples. Median FDR values per muta�on type are shown and they represent the frac�on of muta�ons called in RNA-seq for which there are no exome reads suppor�ng the same variant (see Methods and Supplementary Figure  1c ). Error bars represent the 95% confidence interval a�er bootstrapping 10,000 �mes.
associations in several brain regions, and in particular the basal ganglia (Supp. Fig. 4a ), supporting the hypothesis that somatic mutation load could contribute to the increasing risk of neurodegenerative diseases with age 24 .
In addition to age, other biological factors also contributed to somatic mutations. For example, women show a much greater mutation load in breast than men (Fig 2b; Wilcoxon p = 1.7x10 -8 ). We also observed female-biased mutations (BH-FDR<0.1) in subcutaneous adipose, visceral adipose, liver, and the adrenal gland; in contrast, we found no significant male-biased mutations after multiple hypothesis correction (Supp. Fig. 4c ; Supp. Table 6 ). Ethnicity can also affect mutation rates: we found a significant increase of C>T mutations in Caucasian sun-exposed skin compared to non-exposed skin, but no corresponding difference in African-Americans (Fig.  2c , Supp. Fig. 4b ), likely due to protection against UV radiation provided by higher melanin content. Finally, we observed that the number of stem cell divisions in a tissue was weakly correlated with mutation load (see Supp. Note 1, Supp. Fig. 5 ).
To investigate the role of natural selection on deleterious somatic mutations, we examined the variant allele frequency (VAF) within every sample where a given mutation was observed. If mutations are subject to negative selection, we would expect it be acting most weakly on synonymous mutations that do not change the amino acid sequence; more strongly on missense variants that change an amino acid; and most strongly on nonsense mutations that introduce a premature termination codon. Indeed, this was the pattern we observed, with synonymous variants having significantly higher VAF than both missense and nonsense variants ( Fig. 2d ).
Since our mutations are called from the transcriptome, these results could be influenced by Nonsense Mediated Decay (NMD), which degrades transcripts containing premature termination codons. While we did observe evidence of NMD (Supp. Fig. 4d ), we found that nonsense mutations in the last exon of genes -which are not subjected to NMD 25 -still have significantly lower VAF compared to synonymous and missense mutations (Wilcoxon p = 1.9x10 -213 and p = 5.6x10 -150 , respectively; Supp. Fig. 4d ), confirming the existence of negative selection against nonsense mutations. Therefore, in contrast to what has been observed in cancer 26 , we found evidence of negative selection acting against both missense and nonsense mutations.
Somatic mutation profiles are tissue-specific and associated with chromatin state
To visualize the tissue-specificity of somatic mutational patterns, we applied t-SNE 27 to the full set of mutations called in each of the 7584 tissue samples (including the two bp flanking each mutation; see Methods; Fig 2e) . We then used a silhouette score (SS) to quantify clustering of samples in this two-dimensional space (see Methods), where a value SS = 1 indicates samples that are maximally clustered within a group, and a value SS=0 means that samples are equidistant to samples within vs. outside a group. Grouping samples by their donor-of-origin results in a mean SS = 0, no different than expected by chance ( Fig. 2f ). However, grouping samples by tissue resulted in values 0.7 > SS > 0.1, suggesting tissue-specific mutation patterns. Spleen, blood, skin, liver, and esophagus mucosa exhibited the most coherent profiles (Fig. 2f, Supp. Fig. 6a,d) ; conversely artery, lung, stomach and thyroid had the least consistent profiles (Fig. 2f, Supp. Fig.  6e ,f). Interestingly, some tissues cluster together as shown by SSs obtained by grouping samples from more than one tissue, suggesting shared mutagenic or repair processes (Fig 2f; Blood Skin Sun exposed Breast
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A fr ic a n A m e ri c a n C a u c a s ia n Cross-�ssue analysis of soma�c muta�ons. a, The total number of muta�ons observed in a �ssue depends on the sequencing depth of that �ssue. Sequencing depth is defined as the cumula�ve amount of uniquely mapped reads across all samples of a �ssue. A linear regression line is shown in blue; �ssues above it exhibit more muta�ons than expected by sequencing depth, while �ssues below it show fewer muta�ons than expected. rho is the Spearman coefficient. b, Examples of significant muta�on associa�ons with age and biological sex (see Supplementary Figure 4 and Supp. Table 6 for all �ssue data). Age ranges represent the youngest and oldest quar�les for each �ssue. To control for sequencing depth and other technical ar�facts, muta�on values were obtained as the residuals from a linear regression (see Methods). P-values are from a two-sided Mann-Whitney test. c, Caucasian sun-exposed skin shows a higher percentage of C>T muta�ons compared to sun-protected skin, while no such difference was seen for African-American skin. Pvalues are from two-sided Mann-Whitney tests. d, Median variant allele frequency (VAF) for each muta�on type based on their impact to the amino acid sequence; error bars represent the 95% confidence interval a�er bootstrapping 1000 �mes; p-values are from two-sided Mann-Whitney tests. e, tSNE plot constructed from a normalized penta-nucleo�de muta�on profile (the mutated base plus two nucleo�des in each direc�on; see Methods for normaliza�on details) and all samples in this study. f, Average silhoue�e scores represen�ng the coherence of selected groups of samples from the tSNE space in panel e; a score of 1 represents maximal clustering, whereas 0 represents no clustering (see Methods). Grouping was performed by �ssue-of-origin, or mul�ple �ssues combined (red labels). "Grouped by people" (green label) is an average silhoue�e score a�er grouping samples by their person-of-origin from 20 randomly selected people. The blue dashed line represents the average random score expecta�on a�er permu�ng �ssue labels (see Methods) and the blue stripes are +/-two standard devia�ons. Error bars in points represent the 95% confidence interval based on bootstrapping 10,000 �mes. g, Muta�on load is posi�vely associated with H3K9me3 and/or nega�vely associated with H3K36me3 across most �ssues analyzed. P-value of associa�on was obtained from a linear regression using all chroma�n marks as explanatory variables (see Methods). Gray range denotes non-significant p-values a�er Bonferroni correc�on. 6b,c; e.g. skeletal muscle and heart, SS = 0.38; seven brain regions, SS = 0.53; colon and small intestine, SS = 0.31). These results suggest that the somatic mutation landscape of the transcribed genome is largely defined by tissue-of-origin.
To explore the source of this tissue-specificity, we hypothesized that chromatin may play an important role, as it does in cancer 4, 5 . We assessed the association between tissue-specific mutation rates and five chromatin marks measured across many human tissues by the Roadmap Epigenomics Project 28 (Supp. Table 7 , see Methods). Across most tissues (except brain) there is a strong positive association between mutation rate and a marker for heterochromatin (H3K9me3); conversely, we found strong negative associations with actively transcribed chromatin (H3K36me3; Fig. 2g ). These results suggest that chromatin associations with mutation rates in the human body are nearly ubiquitous and arise prior to cancer development.
Mutational strand asymmetries are widespread and vary across individuals
Cancer mutations often occur preferentially on one DNA strand, either in reference to transcription or to DNA replication (leading vs lagging strand) 29 . Since our mutations are derived from transcribed exons, we focused on transcriptional mutational strand asymmetries.
We observed the strongest asymmetry for C>A mutations, which preferentially occur on the transcribed strand in most tissues except for brain ( Fig. 3a,b ; mean [transcribed/nontranscribed] ratio = 1.6 in non-brain, 0.98 in brain). C>A mutation load on the transcribed strand also showed the greatest variation between individuals ( Fig. 3a,b ). C>A asymmetries were often correlated between different tissues of the same person ( Fig. 3c , Supp. Fig. 7a ), suggesting a common factor can induce an over-accumulation of C>A mutations on the transcribed strand (or equivalently, G>T mutations on the non-transcribed strand) across many of an individual's tissues. This factor is of unknown origin; it could be intrinsic (e.g. genetic), extrinsic (e.g. exposure to a mutagen), or a combination of the two. Interestingly, this same C>A asymmetry has been observed in lung and ovarian cancer 29 and in cell lines exposed to different environmental agents 30 ; our results suggest it is far more widespread, occurring in most tissues except for brain.
Strand asymmetries could potentially arise from RNA-specific edits or transcriptional errors. To test if these are bona fide DNA mutations, we examined exome data from matching blood samples, and observed general agreement between the level of asymmetry per gene as measured by DNA vs. RNA-seq ( Fig. 3d ).
In addition, we found blood samples to have the highest levels for C>T and T>C asymmetries. However, the directionality of these asymmetries suggests that samples with high biases may be driven by the two major types of RNA editing: A>I (represented in our data by T>C on the transcribed strand), and C>U (represented in our data by C>T on the transcribed strand) ( Fig. 3a , right panel). Interestingly, estimating cell type abundances in each blood sample (see Methods) revealed that the abundances of two cell types, resting NK cells and CD8+ T cells, showed the strongest associations with the extent of both of these asymmetries (Supp. Fig 7b,c) . Consistent with this result, these same two cell types have been shown to have increased levels of both types of editing in stress conditions 31 . This suggests that some RNA editing sites may be present in our catalog of somatic mutations, though we did not observe an increased FDR for these two mutation types in blood ( Fig. 1d ), suggesting that RNA editing has not substantially inflated our FDRs. Tissue Z Score
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Tibial Artery mutation strand bias log2(transcribed/non transcribed) Tibial Nerve mutation strand bias log2(transcribed/non transcribed) rho =0.4 p = 1.2ex10 -8 rho =0.17 p = 0.013 rho =0.064 p = 0.32 
Gene expression implicates pathways associated with somatic mutation load
To explore cellular factors accompanying an increase in somatic mutation load across non-disease tissues, we performed an unbiased tissue-level search for genes whose expression was associated-either positively or negatively-with exome-wide mutational load (see Methods). These enrichments may reflect a mixture of causal scenarios: gene expression impacting mutations or vice versa, or both driven by a third variable. Here we focused on the most-abundant C>T mutations; other mutation types are described in the supplement (Supp. Figs. 9,10) .
While most genes were tested in the majority of tissues (Supp. Fig. 8a ), most significant associations were specific to only 1-3 tissues (Bonferroni-corrected p < 0.05; Fig. 4a , Supp. Fig.  8b ). Among genes positively associated with mutation load in multiple tissues (see Methods), we observed enrichments for GO categories that included nucleotide excision repair, cellular transport, cell adhesion, and macroautophagy; and categories including immune response, keratinization, and cell polarity for negative expression-mutation associations ( Fig. 4b , Supp. Tables 8, 9) . Consistent with these results, several of these same processes (e.g. cellular transport, autophagy and cell adhesion) are known to be associated with mutation load in cancer or normal cells [32] [33] [34] .
To further explore the contribution of different DNA repair pathways to mutagenesis, we focused on the associations between the expression of repair pathway members with mutation load. Specifically, we analyzed genes involved in double-strand break (DSB) repair, mismatch repair (MMR), nucleotide-excision repair (NER), base excision repair (BER), the DNA deaminases APOBEC3A/B and the translesion polymerase POLH. We found 14 associations at a <20% FDR, 8 at <10% FDR, and 2 at <5% FDR ( Fig. 4c blue asterisks; Supp. Fig. 8c -g) which are further described in Supplementary Note 2.
We then tested genes in these pathways for consistent associations with mutation load across tissues (see Methods; Fig. 4c , left panel; Supp. Fig. 10a-d ). We observed significant hits from NER (XPA, FDR=0.01; XPC, FDR=0.07; DDB1, FDR=0.07), MMR (MLH1, FDR=0.05; MSH6, FDR=0.16; PMS2 FDR=0.17), and BER (NEIL2, FDR=0.15). The associations were generally in the expected direction, based on what is known about each gene (see Supp. Note 3); for example, all associations of MLH1 were negative, indicating lower expression associated with higher mutation load ( Fig. 4c , Supp. Fig. 8e ). MLH1 silencing contributes to cancer development and mutagenesis 35 , and our results suggest that natural variation of MLH1 expression is associated with mutagenesis across many tissues in the same direction as in cancer.
To further explore factors that may contribute to mutation load, we analyzed the expression of entire pathways or functionally related gene sets in each tissue (see Methods). MMR, BER, and NER are all strongly associated with mutation load in multiple tissues, but with very little overlap among them ( Fig. 4d ; Supp. Fig. 10e -i). As a result, these associations are primarily dominated by just one or two pathways per tissue.
In summary, most transcriptional signatures associated with mutation load are tissuespecific, however, genes associated with mutation load in several tissues are enriched in a number of pathways including DNA repair. These results paint a complex landscape where mutational load across non-disease tissues is associated with a variety of cellular functions. -log 10 (signed pval) 
Nega�ve gene expression associa�ons
Posi�ve gene expression associa�ons Figure 4 . Muta�on load is associated with the expression of genes and pathways. a, Histogram of the number of �ssues for which each gene was significantly (Bonferroni corrected p < 0.05) associated with muta�on load. Associa�ons were es�mated for each �ssue using linear models controlling for popula�on structure and biological and technical cofactors (see Methods). b, Genes whose expression was nega�vely (top) or posi�vely (bo�om) associated with C>T muta�on load in mul�ple �ssues are enriched in these representa�ve GO categories (see Methods and Supp. Tables 8, 9) . c, Individual gene-�ssue associa�ons between C>T muta�ons and expression of genes involved in DNA repair or DNA mutagenesis (right panel). Blue asterisks denote significant associa�ons using a permuta�on-based FDR strategy (see Methods; * FDR < 0.2, ** FDR < 0.1, *** FDR < 0.05). Shown on the le� panel are genes whose expression was associated with muta�on load across all �ssues more than expected by chance at the indicated FDR (see Methods). d, Group-level gene expression associa�ons of the shown pathways and C>T muta�ons across �ssues (see Methods). Heatmap columns in c and d are ordered based on a hierarchical clustering.
Cancer driver genes are enriched for mutations and under positive selection in non-disease tissues
To investigate the extent to which cancer-associated mutations exist in a pre-cancerous state, we calculated the enrichment of all COSMIC 36 cancer point mutations in our mutation maps (see Methods). Many samples were highly enriched (Hypergeometric Bonferroni-corrected p<0.05), with some having more than 20% overlap with COSMIC mutations (Fig. 5a ). In contrast, we observed almost no significant overlaps in a negative control (using a permuted set of mutations per-sample, that conserves mutation frequencies and genomic regions from the original set of mutations; see methods; Supp. Fig. 11a ). Sun-exposed skin had the highest level of overlap (Hypergeometric BH-FDR<0.05), with 100% of samples having significant enrichments, followed by sun-protected skin and skeletal muscle ( Fig. 5a ). We observed the lowest overlaps across the seven brain regions, aorta, and spleen.
Focusing our analysis on a panel of 53 known cancer driver genes 37 (Supp. Table 10 ), we observed mutations in 31 of them (after excluding potential false-positive mutations; see Methods and Supp. Table 11 ). Some tissues showed significantly greater or lower mutation rates across these genes ( Fig. 5b ). Sun-exposed skin was once again the most significant tissue, with several others at FDR < 0.05, such as muscle and heart ( Fig. 5b ). Interestingly, MAP2K1 and RRAS2 are highly mutated in muscle, and IDH2 and PPP2R1A are highly mutated in both heart and skeletal muscle ( Fig. 5c ). Conversely, several tissues-including most brain regions-had significantly lower mutation rates than average in these cancer drivers ( Fig. 5b ).
Observed mutations in cancer driver genes were then classified by their impact on protein sequences. We found that some genes were dominated by missense mutations, such as IDH2, while others showed an excess of synonymous mutations, such as MAP2K1 (Fig. 5d ).
To assess the selective pressures acting on these genes we used a dN/dS approach, which assesses the ratio of non-synonymous to synonymous mutations while accounting for sequence composition and variable mutation rates across the genome 38 (see Methods). dN/dS values close to 1 represent little or no detectable selection, dN/dS>1 suggests positive selection, and dN/dS<1 suggests purifying selection. Our analysis showed that most of these cancer drivers are evolving under positive selection ( Fig. 5e ). Missense mutations had a mean dN/dS=1.06 whereas nonsense mutations had a mean dN/dS=9.14 (indicating over 9-fold enrichment for nonsense mutations compared to the expectation based on synonymous mutations in the same genes); the latter is significantly more than expected from genome-wide values (permutation-based p=0.1 and p=0.009, respectively; Fig. 5e ).
NOTCH1 has been recently observed to evolve under positive selection in non-cancerous skin 15 and esophagus 18, 19 . Consistent with this, we found the highest rates of NOTCH1 mutations in these same two tissues ( Fig. 5c ), with strong signals of positive selection (NOTCH1 missense dN/dS = 1.46, nonsense dN/dS = 14.04). We also observed NOTCH1 mutations at slightly lower rates in the small intestine and tibial artery ( Fig. 5c ).
To further explore the effects of selection on cancer-associated mutations, we performed a VAF analysis (similar to Fig. 2d ). Using the large catalog of COSMIC cancer point mutations (as in Fig. 5a ), we created two subsets of our somatic mutation list: those that have been observed in cancer samples, and those at precisely the same location as a known cancer mutation, but with a different base change (which act as well-matched negative controls). We then separated each . Cancer driver genes evolve under strong posi�ve selec�on, and cancer muta�ons are enriched in healthy �ssues. a, Percentage of COSMIC cancer muta�ons observed per sample and grouped by �ssue; p-values for enrichment were calculated using a hypergeometric test accoun�ng for sequencing coverage, total number of muta�ons per sample, and total number of COSMIC muta�ons, and the three possible alternate alleles that any given reference allele can have (see Methods). P-values are Bonferroni-corrected across all samples. b, Rela�ve muta�on rates of a selected group of 53 genes known to carry cancer driver muta�ons 37 (only 31 of them had at least 1 muta�on in this study); the �ssue-wide average is indicated with the do�ed line. Significant devia�on from the �ssue-wide average was calculated using the binomial distribu�on and the �ssue-wide average muta�on rate. Benjamini-Hochberg FDR: *** (FDR < 0.001), ** (FDR < 0.01), * (FDR < 0.05). c, Individual muta�on rates for each cancer driver gene across all �ssues. d, Percentage of muta�ons for each cancer driver gene stra�fied by impact to amino acid sequence; n is the total number of muta�ons observed in a gene. e, dN/dS values for missense (blue) and nonsense muta�ons (orange) in cancer driver genes calculated using dndsloc 9, 38 (see Methods) ; averages per group are shown as rhomboids and their respec�ve genome-wide averages are shown as dashed lines along with their 95% confidence intervals a�er bootstrapping 10,000 �mes. P-values indicate the probability of observing a higher average dN/dS from 10,000 equally-sized randomly-sampled groups of genes (see Methods). f, Median variant allele frequency (VAF) for each muta�on type based on their impact to the amino acid sequence and colored by their cancer status. Muta�ons "in cancer" (purple bars) are those that overlap with the COSMIC database in both base change and posi�on, and muta�ons "not in cancer" (yellow bars) are those that overlap with COSMIC only in posi�on but not in base change. Error bars represent the 95% confidence interval a�er bootstrapping 1000 �mes; pvalues are from two-sided Mann-Whitney tests. g, Muta�on maps of five cancer driver genes; oncogenic state was obtained from oncoKB 39 , and clustered muta�on annota�ons were obtained from the databases Cancer Hotspots 42 and 3D Hotspots of muta�ons occurring in close proximity at the protein level 43. of these two subsets into three mutation types: synonymous, missense, and nonsense. In all three cases, the VAFs of the cancer-associated mutations were significantly higher than the matched non-cancer-associated ones (Fig. 5f ). Using the synonymous non-cancer mutations as representative of neutrality (similar to dN/dS), we found that all three cancer-associated mutation types had higher VAF than these neutral proxies ( Fig. 5f ), suggesting the action of positive (and not just weaker negative) selection. Interestingly, the ratio of cancer/non-cancer mutation VAFs was lowest for synonymous (1.4-fold), intermediate for missense (2.0-fold), and highest for nonsense (5.2-fold), suggesting stronger positive selection for more extreme mutations. These results are consistent with the dN/dS analysis in Fig. 5e , which also showed the strongest positive selection on nonsense mutations in cancer driver genes, but the VAF analysis has substantially more power due to the greater number of mutations analyzed. We also found a number of specific mutations manually curated as oncogenic or likely oncogenic from OncoKB 39 (Supp. Table 12 ). For instance, all nonsense mutations that we observed in NOTCH1 have been labelled as oncogenic ( Fig. 5g ). We found many other oncogenic mutations as well; for example, RHOA and RAC1 had oncogenic mutations in their Ras domains ( Fig. 5g ).
Together these results show that cancer mutations are enriched in non-disease tissues and not only do they accumulate in driver genes, but the majority of these genes are evolving under positive selection, suggesting that these mutations increase cellular proliferation well before any cancer is observed.
DISCUSSION
We developed a method to detect rare somatic mutations from RNA-seq data and applied it to over 7,500 tissue samples (Fig. 1) . To our knowledge this is the largest map to date of somatic mutations in non-cancerous tissues.
It has been proposed that somatic mutations contribute to aging and organ deterioration 40 ; consistent with this, we observed a positive correlation between age and mutation burden in most tissues. Interestingly, several brain regions are among the tissues exhibiting stronger age correlation, and somatic mutations have been shown to have a role in neurodegeneration 24 .
We observed largely tissue-specific behaviors and some pervasive observations shared across tissues. Mutation profiles are defined by their tissue-of-origin, mutation maps are delineated by tissue-specific chromatin organization, and transcriptional signatures associated with mutation load are highly tissue-specific. These results suggest that different cell types are subjected to different evolutionary paths that could be dependent on environmental or developmental differences. For example, while most samples exhibit tissue-specific mutation profiles, some others like transverse colon and the small intestine have similar profiles. Additionally, we observed that genes whose expression is associated with mutation load in several tissues are enriched in DNA repair, autophagy, immune response, cellular transport, cell adhesion and viral processes; and while these functions have been implicated in mutagenesis in cancer [32] [33] [34] , our results highlight how expression variation of these genes associates with mutational variation in healthy tissues.
Cancer mutations are enriched across many organs. Muscle and heart tissue are particularly interesting because they have lower-than-expected mutation rates, but those mutations are highly enriched for cancer mutations and had high mutation rates in cancer drivers. Sarcomas are tumors originated from soft tissues -including muscle -that are relatively uncommon and have a low density of point mutations but high copy number variation 41 . Our results show that low mutation rates are also observed in these soft tissues, but compared to tumors, cancer mutations are frequent. The functional implications of this observation will need to be explored in further detail.
Positive selection of driver genes has been recently observed in healthy tissues 15, 18 . Accordingly, we confirmed that NOTCH1 is under positive selection in skin and esophagus. We found other genes positively selected both broadly (e.g. IDH2, CTNNB1, NFE2L2) and with more tissue-specific patterns (e.g. KEAP1 in prostate, thyroid and muscle; RAC1 in skin, esophagus, and breast), which will be important subjects for future studies.
In general, mutations previously observed in cancer studies were found in high abundance across many healthy tissues, and our VAF analysis showed signatures of positive selection acting on them. In contrast, when looking at all mutations and in particular those not previously seen in cancer, we found that missense and nonsense mutations are generally under negative selection. Our results reconcile recent studies reporting prevalent positive 9 or negative 11 selection in somatic evolution, as we find evidence of both co-existing in different sets of mutations.
Our findings paint a complex landscape of somatic mutation across the human body, highlighting their tissue-specific distributions and functional associations. The prevalence of cancer mutations and positive selection of cancer driver genes in non-diseased tissues suggests the possibility of a poised pre-cancerous state, which could also contribute to aging. Finally, our method for inferring somatic mutations from RNA-seq data may help accelerate the study of somatic evolution and its role in aging and disease. Supplementary Table 1 . Average percentage elimination of putative mutation calls by persample false-positive filters across all tissues. Table 2 . Total number of samples per tissue included for the final set of mutation calls. Supplementary Table 3 . List of all somatic mutations identified in this study. Supplementary Table 4 . P-values (-log10[p-value]) for the coefficients of each feature used in a linear regression on the total number of mutations per tissue. Supplementary Table 5 . Average percentage of each mutation type across samples of the given tissue. Supplementary Table 6 . Significant associations between biological sex and mutation load across tissues and mutation types. Supplementary Table 7 . Tissue correspondence between the GTEx 23 and Roadmap Epigenomics projects 28 . Supplementary Table 8 . Significant GO enrichments for genes whose expression is significantly and negatively associated with C>T mutation load across several tissues. Supplementary Table 9 . Significant GO enrichments for genes whose expression is significantly and positively associated with C>T mutation load across several tissues. Supplementary Table 10 . List of cancer driver genes used in this study 37 . Supplementary Table 11 . List of mutations in cancer driver genes after further elimination of potential false positives. , with increasing number of reads suppor�ng the alternate allele (x axis), at different phred sequencing scores (colored lines). Probability is calculated using the right tail of a binomial distribu�on on the number of observed reads suppor�ng a muta�on [X ~ binom(n = coverage, p=10 -Prehd/10 x1/3); Phred-based sequencing error probability is mul�plied by 1/3 to account for three poten�al different bases to mutate]. b, Average muta�on rate is high close to splice junc�ons in RNA-seq (bo�om 2 rows) but not in DNA-seq data (top row). Muta�on rate was calculated by taking the number of muta�ons observed at a given distance from an exon junc�on and dividing it by the number of reads covering posi�ons at that distance. Ver�cal dashed lines represent the point of inflec�on at which muta�on rate stabilizes; we used a 1-bp sliding window to iden�fy the posi�on with maximum absolute difference between muta�on rates of the four bps downstream and the four bps upstream of that posi�on. Error bars are the 95% confidence intervals based on bootstrapping 1,000 �mes. c, DNA soma�c muta�ons called from RNA-seq were validated by assessing the percentage of muta�ons for which there was at least one read suppor�ng the alternate allele in matched exome DNA-seq data (see Methods). The top panel shows the histogram of number of reads suppor�ng the alternate allele in DNA-seq for all muta�ons found in RNA-seq. The bo�om panel shows the same data a�er randomly assigning an alternate allele to the muta�ons called in RNA-seq, effec�vely crea�ng a distribu�on expected by chance (see Methods). X axes were truncated for visual purposes. d, For the method valida�on, we compared RNA-seq-based muta�on calls to DNA-seq data. To address differences in coverage between the two methods we only compared posi�ons with r >= 8 (dashed line; r effec�vely represents the number of expected reads that support the alternate allele in DNA-seq at a posi�on given the alternate allele frequency observed in RNA-seq at that posi�on and the DNA-seq coverage; see Methods), which ensures considering only posi�ons for which reads suppor�ng the alternate allele were expected to be found in DNA-seq given the coverage of that posi�on in both experiments. e, Hyper-mutated samples were iden�fied by applying a linear regression between the number of muta�ons and sequencing depth (Uniquely mapped reads), age, BMI and gender. The observed number of muta�ons was mostly explained by sequencing depth (le� panel) and the expected number of muta�ons agrees for most samples with the observed number muta�ons (middle panel).
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Hyper-mutated samples were tagged as the ones with residuals from the linear regression of >=1,500, meaning they had at least 1,500 muta�ons more than expected (right panel; see Methods for more details). Skin sun-protected Skin sun-exposed Blood a b Supplementary Figure 3 . Muta�on load across different muta�on types in non-disease human �ssues. a, Across all muta�on types, the total number of muta�ons observed in a �ssue is explained by the total sequencing depth of that �ssue. A linear regression line is shown in blue; �ssues above it exhibit more muta�ons than expected by sequencing depth and �ssues below it show fewer muta�ons than expected. Rho is the Spearman coefficient. b, Representa�ve examples for rela�ve contribu�ons of different muta�on types across different �ssues (see Supp. Table 5 for all-�ssue data). Table 6 for all significant associa�ons with sex). d, Related to Figure 2d , median variant allele frequency (VAF) across all muta�ons for each muta�on type based on their impact to the amino acid sequence; nonsense muta�ons were divided into two different groups based on whether they are located in the last exon; error bars represent the 95% confidence interval a�er bootstrapping 1000 �mes; p-values are from two-sided Mann-Whitney tests. Supplementary  Figure 5 . Number of stem cell divisions correlates weakly with muta�on load in human �ssues. Associa�ons between different muta�on types and the number of stem cell divisions of the most abundant cell type for each �ssue 44 . Observed/expected muta�ons (y-axis) were calculated by dividing the number of muta�ons observed in a given �ssue by the predicted number of muta�ons based on the sequencing depth of the �ssue from the linear regression in Figure 2a . Associa�ons between different muta�on types and the number of stem cell divisions of the most abundant cell type for each �ssue 44 . Observed/expected muta�ons (y-axis) were calculated by dividing the number of muta�ons observed in a given �ssue by the predicted number of muta�ons based on the sequencing depth of the �ssue from the linear regression in Figure  2a . Figure 6 . Muta�on profiles cluster by �ssue. a-f, tSNE plots as described in Figure 2e , highligh�ng individual (a,d) and grouped (b,c) �ssues exhibi�ng highly similar within-�ssue muta�on profiles, and two �ssues showing �ssue profiles with weak clustering (e,f).
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Cell type contribution to sample C>T strand bias log2(transcribed/non transcribed) rho = 0.65 p = 2. 0   2500   5000   7500   10000   1 2 3 4 5 6 7 8 9 1011 12 13 14 15 16 17 18 19 2021 22 23 24 25 26 27 28 29 3031 32 33 34 Figure 8 . Gene expression associa�ons with C>T muta�on load. a, Histogram of the number of �ssues in which a gene was tested for associa�on between its expression and C>T muta�on load. A gene was selected to be tested in a �ssue based on having detectable expression in that �ssue (see Methods). b, Histogram of the percentage of �ssues exhibi�ng significant associa�ons (p < 0.05 a�er Bonferroni correc�on) between expression of a gene and C>T muta�on load. c-g, Examples of individual significant associa�ons between C>T muta�on load and expression of DNA repair genes in different �ssues (0.001 < FDR < 0.2, see Fig. 4c ). Muta�on load is normalized by controlling for biological and technical factors (see Methods). Rho is the Spearman correla�on coefficient. 1 0 0 -2 0 2 0 -1 5 1 5 -1 0 1 0 -5 5 -1 0 . MUTYH  OGG1  NTHL1  NEIL2  NEIL1  DDB2  DDB1  XPA  XPC  PMS2  MLH1  MSH6  MSH3  MSH2  EXO1  POLD1  BRCA1  BRCA2  POLH  APOBEC3B Figure 10 . Muta�on load associa�ons with expression of genes involved in DNA repair or DNA mutagenesis. a-d, Individual gene-�ssue associa�ons between different muta�on types and expression of genes involved in DNA repair or DNA mutagenesis (right panels); blue stars denote significant associa�ons using a permuta�on-based FDR strategy (see Methods; * FDR < 0.2, ** FDR < 0.1, *** FDR < 0.05). Shown in the le� panels are genes whose expression was associated across all �ssues more than expected by chance at the indicated FDR (see Methods). e-i, Group-level gene expression associa�ons of the shown pathways and different muta�on types across �ssues (see Methods). Supplementary Figure 11 . Nega�ve controls and filters for cancer muta�on enrichment in non-disease human �ssues. a, Percentage of randomly permuted muta�ons (see Methods) in non-disease �ssues that overlap with cancer muta�on sites (COSMIC) but where the muta�on type disagrees (i.e C>A in one dataset and C>G in the other); p-values for enrichment were calculated using a hypergeometric test accoun�ng for sequencing coverage, total number of muta�ons per sample, and total number of COSMIC muta�ons, and the three possible alternate alleles that any given reference allele can have (see Methods). P-values are Bonferroni-corrected across all samples. FDR is based on the Benjamini-Hochberg method across all samples. b, Histogram of t values (x axis, described in methods) for each muta�on in a panel of 31 cancer driver genes. Muta�ons with high t values account for most of the unique mutated sites in their gene-oforigin, leading to a low diversity in muta�ons of a given gene. These muta�ons are likely systema�c ar�facts and can bias dN/dS ra�os 9 .
Where ci is the count of the mutation type i, sg,i is the number of occurrences of the i sequence context in gene g, eg is the expression in TMP of gene g, and genes are all genes with TPM >= 1 in the given sample. This calculation was performed separately for every sample. We used the tSNE implementation in R (Rtsne) with parameters dims = 2, max_iter = 500, perplexity = 30, pca = TRUE, theta = 0.5.
To quantify the clustering among different groupings in the tSNE two-dimensional space, we calculated a silhouette score (SS) for each group defined in Figure 2f by first obtaining a silhouette score (si) for each sample in each group:
Where ai is the average distance of sample i to all other samples inside the group, and bi is the average distance of sample i to samples outside the group. We then calculated the average score s of all samples in a given group and the 95% confidence intervals based on bootstrapping 10,000 times.
We performed the individual-based grouping by calculating silhouette scores for all tissues from 20 randomly selected individuals and then averaging them. The random expectation was calculated by permuting the tissue labels across samples 10 times, repeating the SS calculation across tissues and then averaging all SSs.
Cell type decomposition for blood and lung samples
We used CIBERSORT 45 to identify the cell type composition of each whole blood sample in the GTEx data. Briefly, CIBERSORT applies a support vector regression on a gene expression profile(s) using reference gene expression signatures from different cell types, and then retrieves the cell type composition from the signatures in the original expression profile(s). We used the online portal (https://cibersort.stanford.edu/) and the default LM22 expression signatures composed of the most prevalent immune cell types. CIBERSORT was run on the blood gene expression profiles with default parameters: 100 permutations and "absolute" mode.
Gene expression associations
To avoid population-based effects for all expression associations analyses in this study we only used self-reported Caucasian people.
For each tissue we used individual gene expression to model mutation counts in a linear regression as follows: D # = E F + H E : : 5IJ :,# + KL # Where x is the expression of a given gene in TPM, cov is a covariate variable and there are n covariates. To estimate the effects of a SNP on the phenotype, g is calculated for each gene in the genome that has a TPM > 1 in at least 20% of the samples. Significance is measured based on the p-value of a non-zero t-test performed on g. P-values are adjusted using Bonferroni correction.
When pi is the vector of mutation loads, we defined it as the residuals after regressing non-biological factors as described previously (see above in "Discovery of mutation associations with biological and non-biological factors"). The covariates included in this model are the first 3 PCs of the whole-genome genotypes, age, sex, and BMI.
In all cases both pi and g were normalized by converting the values into quantiles and mapping them to the corresponding values of the standard normal distribution quantiles, following standard GTEx practices 23 .
Gene Ontology analysis
For gene expression associations with mutation load, we assessed enrichment in GO biological processes using GOrilla 53 . We used as input a ranked list of genes based on the number of tissues they were significant in (and only including genes that were tested in more than the median number of tissues all genes were tested in, p<0.05 after Bonferroni correction, see above in "Gene expression associations") and breaking ties by significance. We then used REVIGO 54 to obtain non-redundant categories.
Expression associations with genomic instability genes
We selected a panel of genes known to be involved in different pathways of DNA repair or translesion replication ( Fig. 4) and performed association analyses between their expression and the mutational load for all different mutation types on a per-tissue basis. We followed the same linear regression strategy as described above in "Gene expression associations". We devised customized strategies to calculate FDRs for individual gene-tissue associations, gene enrichment across all tissues, and pathway (gene group) associations in each tissue.
For individual gene-tissue associations, we calculated an FDR based on the distribution of p-values of the linear regressions from the tests of all genes in the genome (see above for additional filters). Then, for each gene of interest we calculated the FDR as the percentage of genes from all tests that had an equal or lower p-value.
To obtain an FDR of the enrichment for different pathways across tissues, for each pathway of interest we obtained the p-values from the individual linear regressions of each gene. We then created 10,000 groups with randomly selected genes with the same size as the pathway of interest and within the tissue of interest, and performed linear regressions with mutation load (as describe above in "Gene expression associations"). Finally, for each p-value in the original group we calculated the FDR by dividing the percentage of p-values of equal or lower value in all permuted regressions by the percentage of p-values of equal or lower value in the original regressions. For example, if 0.1% of permuted regressions reached p<0.001, compared to 1% of unpermuted regressions, the FDR at p<0.001 would be 0.1/1 = 10%.
Lastly, to calculate FDR for the enrichment of individual genes across all tissues we used a similar strategy as the FDR calculation for gene pathways described in the previous paragraph. We first obtained the p-values of individual linear regression of a given gene across all tissues. We then created a permuted set of p-values from the regressions of one gene from each of the 10,000 permuted groups in all tissues. Finally, we calculated the FDR of the p-values in the original group (one across all tissues) by dividing the percentage of p-values of equal or lower p-value in all permuted regressions by the percentage of p-values of equal or lower value in the original regressions.
Chromatin analysis
To address the influence of chromatin on somatic mutations, we first manually mapped tissues from GTEx to tissues of the Roadmap Epigenomics Project 28 . We were able to do such mapping for 18 tissues (Supp. Table 7) . For each tissue, on a per-exon basis we calculated both mutation rates and signal for H3K36me3, H3K4me1, H3K4me3, H3K27me3, H3K9me3.
To account for sequencing depth (expression) of an exon when calculating mutation rates, we assigned exons to 100 bins based on their sequencing depth, where each bin contains 1% of exons. We then calculated the median number of mutations observed in each bin, and finally the mutation rate per exon was obtained by subtracting expected number of mutations (the median for all exons in that bin) from the observed number for that exon.
Chromatin signal for each exon was obtained from Roadmap ChIP-seq data. We calculated the average base-pair ratios of IP/input obtained from the Roadmap bigwig files. Significance of the association between each chromatin mark and mutation rate was assessed by applying a linear regression on the mutation rate using all chromatin marks as features.
Mutation enrichment in COSMIC cancer mutations
We downloaded the entire set of cancer mutations from COSMIC 36 v86 and we further filtered them to only keep single nucleotide variants without indels. For each sample we calculated the percentage (overlap) of their mutations that are present in COSMIC mutations, and we calculated the significance of the overlap using the integral of the upper tail from a hypergeometric distribution, that is p(X > k), where X follows a hypergeometric distribution with parameters K (number of mutations in sample), n (number of COSMIC mutations whose positions were covered by >= 40 reads in the RNA-seq sample), N x 3 (the total number of base pairs covered by >= 40 reads in the RNA-seq sample multiplied by the three possible alternate alleles that any reference can have), and k (the overlap of mutations, K and n). As a control, for each sample this calculation was repeated using a permuted set of mutations. This set was constructed by randomly selecting genomic positions that were covered by >=40 reads in the sample and then mutations were simulated in those positions, importantly we conserved the number of reference alleles and their corresponding alternate alleles from the original mutations in this permuted set.repeated.
dN/dS analysis
To calculate dN/dS ratios we applied a previously described method 38 that uses a Poisson distribution to model the number of mutations with different impacts (i.e. synonymous vs nonsynonymous). Briefly, the Poisson distribution is based on the relative content of a mutation type (e.g. C>T) across all types, the total content of that mutation type, and the density of mutations per site. For non-synonymous mutations an extra parameter represents the effect of selection (dN/dS), and maximum-likelihood estimates are calculated by Poisson regression for all parameters. This framework accounts for different substitution rates across different genes as well as sequence composition. We used dndsloc, which is the implementation of this method in R 9 (https://github.com/im3sanger/dndscv).
Mutation analyses on cancer driver genes
We downloaded the list of genes known to contain at least one cancer driver mutation, based on the latest TCGA publication on cancer driver genes 37 (Supp. Table 10 ). Since we did more in depth analysis in this set of genes, we further removed potential false-positive mutation calls that could bias gene-level analysis but are not necessarily an issue for genome-wide analysis. For some of these genes we observed a high number of total mutations but low number of unique mutations, in other words some mutations accounted for most of the unique mutated sites, which has been previously described as an artifact 9 . To flag these events, for each mutation we calculated a metric t as the ratio of the counts of that mutation divided by the unique number of mutations found in the gene-of-origin. Mutations with high t values account for most of the unique mutated sites in their gene-of-origin, leading to a low diversity in mutations of a given gene. These mutations may be artifacts and can bias dN/dS ratios 9 . The distribution of t values for mutations in this set of genes was bimodal (Supp. Fig. 11b ) and we therefore excluded mutations with r > 3.5.
To assess the mutation load on these genes and their significance, for each tissue we calculated the mutation rate of these genes, and then calculated whether this mutation rate was higher or lower than expected from the overall mutation rate on these genes across all tissues (Fig. 5b) . To do so we calculated the overall mutation rate in cancer driver genes across all tissues (k) and then for each tissue we calculated the probability of the number of observed mutations (n) in these genes using the binomial distribution [X ~ binom(n,k)]. For tissues showing more mutations than expected we used the integral of the right tail of the binomial distribution to calculate the probability of observing n mutations, and conversely for tissues showing fewer mutations we used the integral of the left tail of the distribution. FDR was calculated using Benjamini-Hochberg method on the p-values.
We annotated the oncogenic status for the mutations in these driver genes using the oncokb 39 tool MafAnnotator.py.
